Bildkälla: Stockfoto

Asarina Pharma: Q2’21: A Shift of Focus - Redeye

There are no big surprises in the Q2’21 financials of Asarina Pharma. After the disappointing phase 2a readout for sepranolone in menstrual migraine, we now shift our focus to Tourette’s.

There are no big surprises in the Q2’21 financials of Asarina Pharma. After the disappointing phase 2a readout for sepranolone in menstrual migraine, we now shift our focus to Tourette’s.
Börsvärldens nyhetsbrev
ANNONSER